Stratasys Ltd. (NASDAQ:SSYS), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report on Form 20-F, which contains Stratasys' audited annual financial statements for 2024, can be accessed on the SEC's website at http://www.sec.gov, as well as via the Company's investor relations website at http://investors.stratasys.com/financial-information. The Company will deliver a hard copy of its 2024 annual report on Form 20-F, including its complete audited financial statements, free of charge to its shareholders, upon request to Yonah Lloyd, Chief Communications Offic

Fourth quarter revenue of $150.4 million, compared to $156.3 million in the prior year period Fourth quarter GAAP net loss of $41.9 million, or $0.59 per diluted share, which includes $30.1 million non-cash impairment of an equity investment Fourth quarter Non-GAAP net income of $8.5 million, or $0.12 per diluted share Full year revenue of $572.5 million, compared to $627.6 million in 2023 Full year GAAP net loss of $120.3 million, or $1.70 per diluted share, and non-GAAP net income of $4.2 million, or $0.06 per diluted share Fourth quarter positive operating cash flow of $7.4 million Full year positive operating cash flow of $7.8 million, resulting in $150.7 million cash equiv

Stratasys Sets Important ESG Standards in the 3D Printing Industry The Company is a Top Choice Sustainable Additive Manufacturing Operations and Solutions Provider Stratasys Ltd. announced today that it received its first-ever EcoVadis certification, achieving a Silver sustainability rating, placing in the 90th percentile joining the top 10% of all companies assessed globally. This milestone displays the company's dedication to responsible business practices that create a positive impact on the environment, society, and all stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250226688746/en/Stratasys achieved a Silv

Cantor Fitzgerald initiated coverage of Stratasys with a rating of Overweight and set a new price target of $24.00

Needham upgraded Stratasys from Hold to Buy and set a new price target of $15.00

William Blair upgraded Stratasys from Underperform to Mkt Perform

S-8 - STRATASYS LTD. (0001517396) (Filer)

20-F - STRATASYS LTD. (0001517396) (Filer)

6-K - STRATASYS LTD. (0001517396) (Filer)

Transaction at a Premium Underscores Leading Position in the Additive Manufacturing Industry and Positions Stratasys to Drive Growth Strengthens Balance Sheet to Capture Market Opportunities Fortissimo's Founding and Managing Partner, Yuval Cohen, to Join the Stratasys Board Stratasys Ltd. (NASDAQ:SSYS) ("Stratasys" or the "Company"), a leader in polymer 3D printing solutions, today announced that Fortissimo Capital ("Fortissimo"), a leading Israeli private equity fund investing in technology and industrials, has entered into an agreement to invest $120 million in the Company, acquiring approximately 14% of Stratasys' issued and outstanding ordinary shares through a direct purchase of

Stratasys highlights achievements in environmental, social, and governance initiatives, cementing its position as a supplier of choice for sustainable AM-enabled production solutions. Stratasys Ltd. (NASDAQ:SSYS) today announced the publication of its third Mindful Manufacturing™ ESG (Environment, Social, and Governance) and Sustainability Report. Prepared in accordance with the Global Reporting Initiative (GRI) and referencing SASB (Sustainability Accounting Standards Board) standards, the report underscores Stratasys' commitment to ESG excellence and enterprise risk management through best-in-class corporate governance, a people-first approach, meaningful social impact, and robust envir

Medical facilities and device manufacturers previously limited by constraints can now create patient-specific models to enhance surgical preparation, elevate patient outcomes, and fast-track innovation Stratasys Ltd. (NASDAQ:SSYS) today announced the launch of its J5™ Digital Anatomy™ 3D printer, the latest innovation designed to address the growing demand for cost-effective, high-fidelity anatomical models. This Stratasys innovation is designed to enable hospitals, medical device manufacturers and research institutions to enhance patient outcomes, streamline operations and bring products to market faster. This press release features multimedia. View the full release here: https://www.bu

Fourth quarter revenue of $150.4 million, compared to $156.3 million in the prior year period Fourth quarter GAAP net loss of $41.9 million, or $0.59 per diluted share, which includes $30.1 million non-cash impairment of an equity investment Fourth quarter Non-GAAP net income of $8.5 million, or $0.12 per diluted share Full year revenue of $572.5 million, compared to $627.6 million in 2023 Full year GAAP net loss of $120.3 million, or $1.70 per diluted share, and non-GAAP net income of $4.2 million, or $0.06 per diluted share Fourth quarter positive operating cash flow of $7.4 million Full year positive operating cash flow of $7.8 million, resulting in $150.7 million cash equiv

Schedules Fourth Quarter 2024 Conference Call for 8:30 a.m. ET on Wednesday, March 5, 2025 Stratasys Ltd. (NASDAQ:SSYS) ("Stratasys" or the "Company"), a leader in polymer 3D printing solutions, today announced unaudited preliminary approximate financial results for the fourth quarter 2024. Preliminary Fourth Quarter 2024 Results Revenue of $150.1 to $150.5 million, with hardware sequentially higher and consumables sequentially lower compared to the third quarter of 2024 GAAP gross margin of 46.0% to 46.5%, non-GAAP gross margin of 49.4% to 49.7%. GAAP operating loss of $13.3 to $14.4 million, non-GAAP operating income of $9.0 to $9.5 million GAAP net loss of $15.3 to $16.5

-Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -Innovative breast implant technology designed to address a $3.0 billion market opportunity -Cash and cash equivalents balance as of September 30, 2024 was $15.4 million -Conference call to be held today at 10:00 a.m. U.S. EDT – REHOVOT, Israel, Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration

SC 13G/A - STRATASYS LTD. (0001517396) (Subject)

SC 13G/A - STRATASYS LTD. (0001517396) (Subject)

SC 13G/A - STRATASYS LTD. (0001517396) (Subject)